Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The latest health news covers the European Medicines Agency supporting Novo Nordisk’s drug for heart failure in obese ...

EMA endorses Novo Nordisk's Wegovy for treating heart failure and lowering heart risks in obese patients. Second approval ...

Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...